This report evaluates the effect of prior administration of several clinically used Sn(II)-containing agents on in vivo distribution of 99mTc. Abnormal binding of 99mTc to red blood cells can occur after administration of pertechnetate to patients who have previously received tin-containing agents. Increased blood levels of tin from other causes may have similar effects.